Elmar Schilling

Elmar Schilling is an experienced professional in the field of molecular diagnostics and research and development, currently serving as Senior Director of R&D at Werfen since April 2025. Prior to this role, Schilling was the Chief Technology Officer at Omixon from October 2019 to April 2025, where the focus was on advancing the flagship product, Holotype HLA™, a leading solution in NGS-based HLA genotyping used in over 20 hospitals worldwide. With extensive experience at Eurofins Genomics from July 2010 to September 2019, Schilling held various leadership positions overseeing NGS innovation, quality assurance, and project management. Earlier academic contributions included roles as a postdoctoral researcher and PhD student at Regensburg University Medical Center, complemented by a visiting scientist position at The University of North Carolina at Chapel Hill. Schilling holds a Dr. rer. nat. degree from Regensburg University Medical Center and a Diploma in Biology with a focus on Genetics and Developmental Biology from the University of Regensburg.